Momenta Pharmaceuticals, Inc.

Jan Hillson

David J King

James Meador, Iii

Leona E Ling

Marilyn Kehry

Nathaniel J Washburn

Sucharita Roy

Anthony Manning

James Iii Meador

The present application features antibodies that bind to human neonatal Fc receptor (FcRn). These anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject. These anti-FcRn antibodies are also useful, e.g., to decrease pathogenic antibody transport across the placenta of a pregnant subject, to increase pathogenic antibody catabolism in a pregnant subject, and to treat an antibody-mediated enhancement of viral disease in a fetus or a neonate.

FcRn antibodies and methods of use thereof

Growing community of inventors

Cambridge, MA, United States of America

Jan Hillson